Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) EBIT Margin: 2020-2022

  • SELLAS Life Sciences Group's EBIT Margin fell 163411.00% to -1,673.50% in Q1 2022 from the same period last year, while for Mar 2022 it was -378.90%, marking a year-over-year change of. This contributed to the annual value of -4,195.00% for FY2022, which is 386218.00% down from last year.
  • As of Q1 2022, SELLAS Life Sciences Group's EBIT Margin stood at -1,673.50%, which was down 614.05% from -234.37% recorded in Q2 2021.
  • In the past 5 years, SELLAS Life Sciences Group's EBIT Margin registered a high of -39.39% during Q1 2021, and its lowest value of -1,673.50% during Q1 2022.
  • Over the past 3 years, SELLAS Life Sciences Group's median EBIT Margin value was -226.63% (recorded in 2021), while the average stood at -541.54%.
  • Data for SELLAS Life Sciences Group's EBIT Margin shows a maximum YoY slumped of 163,411bps (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows SELLAS Life Sciences Group's EBIT Margin stood at -218.89% in 2020, then reached -234.37% in 2021, then tumbled by 163,411bps to -1,673.50% in 2022.
  • Its EBIT Margin stands at -1,673.50% for Q1 2022, versus -234.37% for Q2 2021 and -39.39% for Q1 2021.